Cebranopadol

Generic Name: Cebranopadol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₇FN_₂O

CAS Number: 863513-91-1

Unique Ingredient Identifier: 7GDW9S3GN3

Background: Cebranopadol has been used in trials studying the treatment of Pain, Neoplasms, and Chronic Pain.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

Phase 3

Active, not recruiting

Conditions: Acute Pain

Interventions: Drug: Placebo
Drug: Cebranopadol

First Posted Date: 2024-08-09

Last Posted Date: 2024-12-13

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 300

Registration Number: NCT06545097

Locations: 🇺🇸
ALLEVIATE 1 Site 001106, Little Rock, Arkansas, United States
🇺🇸
ALLEVIATE 1 Site 001110, Bellaire, Texas, United States
🇺🇸
ALLEVIATE 1 Site 001112, Miami, Florida, United States

and more 1 locations

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Phase 3

Recruiting

Conditions: Acute Pain

Interventions: Drug: Oxycodone IR
Drug: Cebranopadol
Drug: Placebo

First Posted Date: 2024-05-21

Last Posted Date: 2024-12-13

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 240

Registration Number: NCT06423703

Locations: 🇺🇸
Alleviate 2 001113, Houston, Texas, United States
🇺🇸
ALLEVIATE 2 Site 001111, San Antonio, Texas, United States
🇺🇸
ALLEVIATE 2 Site 001108, Sheffield, Alabama, United States

and more 7 locations

CORAL XT - Open-label Extension Trial of the CORAL Trial

Phase 3

Completed

Conditions: Pain
Neoplasms
Chronic Pain

Interventions: Drug: Cebranopadol

First Posted Date: 2014-01-09

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 76

Registration Number: NCT02031432

Locations: 🇧🇬
BG008, Sofia, Bulgaria
🇧🇪
BE001, Sint-Niklaas, Belgium
🇧🇬
BG001, Shumen, Bulgaria

and more 19 locations

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

Phase 3

Terminated

Conditions: Pain
Neoplasms
Chronic Pain

Interventions: Drug: Morphine Prolonged Release
Drug: Cebranopadol

First Posted Date: 2013-10-17

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 200

Registration Number: NCT01964378

Locations: 🇭🇺
HU004, Gyula, Hungary
🇧🇬
BG003, Sofia, Bulgaria
🇧🇬
BG004, Varna, Bulgaria

and more 39 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy